Latest news
Did Alkermes’ (ALKS) Profit Slide and Cash-Conserving Moves Just Shift Its Investment Narrative? - simplywall.stsimplywall.st · Sun, 09 Aug 2026 09:37:03 GMTTakeda approval ushers in new wave of sleep drugs - BioPharma DiveBioPharma Dive · Thu, 06 Aug 2026 16:10:45 GMTMajor Decision: Nancy Snyderman Exercises Options, Realizing $116K At Alkermes - BenzingaBenzinga · Tue, 04 Aug 2026 15:01:34 GMTAlkermes (NASDAQ:ALKS) EVP David Joseph Gaffin Sells 2,034 Shares of Stock - MarketBeatMarketBeat · Tue, 04 Aug 2026 01:41:01 GMTAlkermes (ALKS) EVP, CLO David Gaffin Sells 2,034 Shares - GuruFocusGuruFocus · Mon, 03 Aug 2026 07:00:00 GMTWhy Alkermes (ALKS) Is Down 7.4% After Q2 Profit Drop And New Equity Shelf Filing - simplywall.stsimplywall.st · Sat, 01 Aug 2026 08:29:29 GMTIs Alkermes (ALKS) Priced For Orexin Success Or Too Rich? - Yahoo FinanceYahoo Finance · Sat, 01 Aug 2026 08:12:48 GMTAlkermes (ALKS) Reported Mixed Q2 Results, Does It Look Fairly Valued? - Yahoo FinanceYahoo Finance · Sat, 01 Aug 2026 00:15:00 GMT